Secukinumab Shows Promise for Polymyalgia Rheumatica
A phase 3 trial has reported topline data on secukinumab for patients with polymyalgia rheumatica (PMR), a common inflammatory rheumatic disease affecting adults over 50.
PMR is characterized by acute pain and stiffness in the shoulders, neck, and hips. Secukinumab, a human interleukin-17A antagonist, is currently approved for treating various conditions, including plaque psoriasis and psoriatic arthritis.
- Secukinumab is marketed under the brand name Cosentyx.
- The REPLENISH trial (NCT05767034) evaluated secukinumab's safety and efficacy in 381 adults with PMR.
No direct quotes available in the text.
Author's summary: Secukinumab may offer a new treatment option for polymyalgia rheumatica.
More News
- Student death remains the routine at Middlebury - The Middlebury Campus
- Half of Illinois students reading at grade level, fewer in math under loosened standards
- Higher mortality rates found in veterans with epilepsy after traumatic brain injury
- DCU Consortium awarded €2.3m in Government Disruptive Technologies Innovation Funding | School of Chemistry
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Danielle Smith: Balancing the budget gets a lot easier if you build a pipeline
- How GenAI Became a Disruptive Force in CS Higher Education – Communications of the ACM
- Palestine 36 review: an engaging historical drama
- Just 2-in-5 Chicago students read at grade level under lowered proficiency standards